SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: A.J. Mullen who wrote (819)6/2/2004 1:34:05 AM
From: Icebrg  Read Replies (2) of 2240
 
Ashley

I believe that there were a couple of commercial considerations that made metastatic melanoma a suitable target.

1. There are no approved effective treatments for second-line metastatic melanoma today. That should mean that the road to approval (if efficacy can be proved) should be relatively easy.

2. Medarex needs a cancer vaccine to work in combination with MDX-010. I suspect that they very much preferred to start with to work with a vaccine where no other companies were involved.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News